Study on effect of gypenosides on insulin sensitivity of rats with diabetes mellitus via regulating NF-κB signaling pathway.
10.19540/j.cnki.cjcmm.20210527.401
- Author:
Kui-Niu ZHU
1
;
Sha-Sha TIAN
2
;
Hui WANG
2
;
Yu-Shan TIAN
3
;
Gui-Zhang GU
1
;
Yao-Yao QIU
1
;
Lu ZHANG
1
;
Hong-Xia YANG
1
Author Information
1. Huzhou Institute for Food and Drug Control Huzhou 313000, China.
2. College of Pharmaceutical Science, Zhejiang Chinese Medical University Hangzhou 311402, China.
3. Jiangsu Key Laboratory of Traditional Chinese Medicine Evaluation and Translational Research, China Pharmaceutical University Nanjing 211198, China.
- Publication Type:Journal Article
- Keywords:
NF-κB signaling pathway;
gypenosides;
inflammation;
insulin sensitivity;
type 2 diabetes mellitus
- MeSH:
Animals;
Diabetes Mellitus, Experimental/drug therapy*;
Diabetes Mellitus, Type 2/genetics*;
Gynostemma;
Insulin;
Insulin Resistance;
NF-kappa B/metabolism*;
Plant Extracts;
Rats;
Signal Transduction
- From:
China Journal of Chinese Materia Medica
2021;46(17):4488-4496
- CountryChina
- Language:Chinese
-
Abstract:
This study focused on the ameliorative effects of gypenosides(GPS) on insulin sensitivity and inflammatory factors in rats with type 2 diabetes mellitus(T2 DM) and explored their possible molecular mechanisms. After the successful establishment of T2 DM model, diabetic rats were randomly divided into four groups, including model group, GPS groups(200, 100 mg·kg~(-1)) and metformin group(100 mg·kg~(-1)), with healthy rats serving as the control. After 6-week intragastric administration, fasting blood glucose(FBG) and oral glucose tolerance were examined. The levels of insulin, C-peptide, tumor necrosis factor-α(TNF-α), interleukin-1β(IL-1β), interleukin-6(IL-6) and C-reactive protein(CRP) in serum were examined. Then the homeostasis model assessment of insulin resistance(HOMA-IR) and insulin sensitivity index(ISI) were calculated. The protein expression levels of phosphorylated insulin receptor substrate-1(p-IRS-1) and phosphorylated protein kinase B(p-Akt) in skeletal muscle were measured by Western blot, as well as those of phosphorylated inhibitor of nuclear factor-κB(NF-κB) kinase β(p-IKKβ), phosphorylated alpha inhibitor of NF-κB(p-IκBα) and phosphorylated p65 subunit of NF-κB(p-p65) in adipose tissue. The relative expression levels of glucose transporter 4(GLUT4) mRNA in skeletal muscle and NF-κB mRNA in adipose tissue were measured by qRT-PCR, and the morphological changes of pancreatic tissue were observed. Compared with the model group, the GPS groups witnessed significant decrease in FBG, marked amelioration of impaired oral glucose tolerance and significant increase in ISI. Further, the high-dose GPS group saw significantly reduced HOMA-IR, TNF-α, IL-1β and CRP, significantly increased expression levels of p-IRS-1(Tyr), p-Akt and GLUT4, and markedly inhibited p-IRS-1(Ser), p-IKKβ, p-IκBα, p-p65 and NF-κB. The concentration of CRP and the expression levels of p-IRS-1(Ser), p-IKKβ, p-IκBα and NF-κB were remarkably reduced in the low-dose GPS group. However, GPS was found less effective in the regulation of serum insulin, C-peptide and IL-6 levels and the alleviation of pancreatic islet injury. The results indicated that GPS can reduce FBG and improve insulin sensitivity in diabetic rats possibly by regulating the NF-κB signaling pathway, inhibiting inflammation, and thereby regulating the expression of key proteins in the insulin signaling pathway.
